Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer's Drug Trials

Pharma giants AstraZeneca and Eli Lilly have scrapped two late-stage trials of an experimental Alzheimer’s drug they were co-developing, the latest blow in the long quest to find a breakthrough for the memory-robbing disorder.

Provided by EUPB - Read the full story at the source site.
Read The Full Story

Top News